Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
about
sameAs
Rofecoxib for rheumatoid arthritisRofecoxib for osteoarthritisCOX-2 inhibitors: a CLASS act or Just VIGORously promotedAcute coronary disease Athero-Inflammation: Therapeutic approachCox-2: where are we in 2003? - Cardiovascular risk and Cox-2 inhibitorsCOX-2: Where are we in 2003? - Be strong and resolute: continue to use COX-2 selective inhibitors at recommended dosages in appropriate patientsCOX-2: where are we in 2003?--distinction from NSAIDs becoming blurredIs it always unethical to use a placebo in a clinical trial?NSAIDs and Cardiovascular Diseases: Role of Reactive Oxygen SpeciesNSAIDs: gastroprotection or selective COX-2 inhibitor?Parecoxib: a shift in pain management?The safety of rofecoxibCardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balanceCardiovascular hazard of selective COX-2 inhibitors: myth or reality?Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategiesIncreased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugsCyclo-oxygenase-2 selective inhibitors and nonsteroidal anti-inflammatory drugs: balancing gastrointestinal and cardiovascular riskEULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT).NSAIDs in the Acute Treatment of Migraine: A Review of Clinical and Experimental DataTrends in hospital admissions for adverse drug reactions in England: analysis of national hospital episode statistics 1998-2005.Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillanceDifferences in outcomes of patients with congestive heart failure prescribed celecoxib, rofecoxib, or non-steroidal anti-inflammatory drugs: population based study.A cohort study to evaluate cardiovascular risk of selective and nonselective cyclooxygenase inhibitors (COX-Is) in arthritic patients attending orthopedic department of a tertiary care hospitalThe efficacy of parecoxib on systemic inflammatory response associated with cardiopulmonary bypass during cardiac surgery.Advances in the treatment of rheumatoid arthritis: old versus new therapies.The double-edged sword of COX-2 selective NSAIDsCochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review.Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors.Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects.Cost-effectiveness of different postoperative analgesic treatments.Association between anti-TNF therapy for rheumatoid arthritis and hypertension: a meta-analysis of randomized controlled trials.Cardiovascular effects of selective cyclooxygenase-2 inhibitors.Cardiovascular risk and COX-2 inhibition in rheumatological practice.Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.Causal Inference for Meta-Analysis and Multi-Level Data Structures, with Application to Randomized Studies of Vioxx.Celecoxib and cardiovascular risks.Comparative cardiovascular safety of traditional nonsteroidal anti-inflammatory drugs.Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.Cardiovascular risks of cyclooxygenase inhibition.Safe pharmacologic treatment strategies for osteoarthritis pain in African Americans with hypertension, and renal and cardiac disease.
P2860
Q24244836-60BD83FA-CA37-45D1-9485-FC8E1C197526Q24244871-8AAA9030-8FF6-445A-9E86-F2E73CFE7B39Q24529085-D8AE3C8A-834C-4ADA-8BE0-A39DECB030E6Q24793068-D8F17DE6-CDA0-4A9A-81F6-648BC64D7547Q24796005-0DD9A748-2D53-46C0-AC40-0D311DDB499CQ24796193-4AB8336E-96DD-490C-9A6D-7C427CBDC3F1Q24804373-A3A01E64-BDFA-455B-976E-4B556E859050Q24805408-D55C3A06-F352-44BF-B734-7643CAFD8D24Q26784322-7C18FD87-B0B9-4312-AB6F-2BEB161D494CQ28168965-6CED8C3B-BCE1-4E7A-A40A-D3CB892ECC47Q28174376-9D02B625-90F2-4142-995A-347F19507652Q28176535-8CB69C26-6C14-4725-998B-55C787FDA9CEQ28191924-22A86EE3-7F98-4114-8442-F555D73DC8BAQ28198746-F43B63EC-D9FF-49DE-A66A-9C6DE2D8918CQ28200569-8683050B-2371-4662-A169-107049C78C0BQ28218432-0057F587-289A-4D94-B6B6-327808CE88D7Q28219220-34EF7DD8-06F4-4130-865E-3AAB6464E1ACQ31119321-56F33690-A997-459F-90C6-303DBC84DCF5Q31135314-E3D7CF22-220E-4B0A-BBAB-F56EAE024550Q33300293-FEA3DA8C-76CE-459B-8070-4AE93EDBAF5DQ33516504-4FB7C340-D65F-4EB7-9C9F-A59E0646DA5EQ33941101-8DBFA35B-A0AA-4FE8-AE4E-65B0A0BA2D9AQ34259503-01C00B0A-E2BD-403E-920D-85189EB4602BQ34640836-7A505D02-A157-4C82-A7D6-9817C8381CD6Q34706876-B09C0243-1F5C-42B8-980F-80B48B5AF7E6Q34994656-FA2CA205-1D66-4BE5-90DB-A28F6166C70CQ35082900-3422F6E0-4B69-4152-A654-D0C1898DE70CQ35083808-FF3B0255-BE88-4DC4-938A-EF896A25342DQ35195182-37943AF2-9BE3-42E9-AD13-36FF5B9BA65DQ35207578-4AF3D8CA-A60A-4955-A836-FF7A5F913D55Q35599025-88CE6983-5114-4365-8AF0-9BB54EE98101Q35777371-3C2CCCCA-1778-4D5E-B1D1-F12BF990D787Q35896154-C3636908-C911-4154-AC2F-311965011FF8Q36013803-4E5232AD-0AD2-409D-9928-1E3155C7DC2AQ36070087-073DE3D7-3F6D-49D0-939E-F96EEAAF7941Q36299969-9042CC23-162B-438E-9059-0E81338FDF05Q36349740-6BEED4B4-D5D1-4644-98FD-D3067D4F0445Q36486905-5FFA6C0C-A7C9-4B4E-B75F-5953DA15E9BFQ36520638-F07F4B86-4561-4EB6-8882-69C6F1BA5EADQ36559595-6B43D534-B4B8-4651-A494-60B20D7B234E
P2860
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
description
2001 nî lūn-bûn
@nan
2001 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@ast
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@en
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@nl
type
label
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@ast
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@en
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@nl
prefLabel
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@ast
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@en
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@nl
P2093
P356
P1433
P1476
Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib
@en
P2093
M A Konstam
R S Sperling
P304
P356
10.1161/HC4401.100078
P407
P577
2001-11-06T00:00:00Z